OBJECTIVES:

With prevalence of (RA ) 0.3% in Egypt with characterization of younger age at disease onset, lower frequency of extra articular manifestations, more frequent poly articular pattern at disease onset and less erosive disease,

With for a law middle income country with limited resources the previous information might lead to increase of economic burden for Rheumatoid Arthritis for the payer side also the need was raised can new innovative products play a role for enhancement patient’s outcomes and reducing economic burden for Rheumatoid Arthritis.

The objective for this study is to determine economic evaluation for Golimumab vs Disease-modifying anti-rheumatic drugs (DMARDs) and other Biological products for reducing economic burden for Rheumatoid Arthritis IN Egypt.

METHODS:

Markov model was developed the structure of this model reflects the natural history of RA. The model conforms to real practice of management of RA in Egypt and was validated by experts. No head-to-head trials analyzing the efficacy of Golimumab compared with other active treatment options were available. This leaded to network meta-analysis

Was conducted using a literature search covering Medline, Scopus, Cochrane library, ACP Journal club and Web of Science was performed. Sensitivity analyses were performed for ACR20 and ACR50 responses based on NICE recommendations.

RESULTS:

For early RA and naive to (DMARDs) incremental QALY gained for Golimumab was (1,334.4) QALY vs (1,331.8) QALY for (DMARDs). For inadequate response to (DMARDs) incremental QALY gained for Golimumab was (1, 4 34) QALY vs (1,331.8) QALY. For (DMARDs)

For an inadequate response to at least one TNF inhibitor incremental QALY gained for Golimumab was (1.443.3) QALY vs range (1,331.8 to 1,335 ) QALY for other TNF inhibitor.

CONCLUSIONS:

Using Golimumab as a priority for treatment Rheumatoid Arthritis might have a positive impact for reducing economic burden for disease plus enhancements for patients out comes.